Amgen plans to open a new technology and innovation site in Hyderabad, India.
The site, known as Amgen India, will accelerate digital capabilities across the global organisation to further advance Amgen's pipeline of medicines.
Amgen India will be located in HITEC City, a suburb of Hyderabad, occupying six floors of the RMZ Spire Tower 110.
The city of Hyderabad, located in the state of Telangana, was selected for its world-class talent across medicine, life sciences and data sciences and the rapidly advancing field of artificial intelligence (AI). The site can accommodate up to 3,000 people and will be operational in Q4 2024.
"At a time when a quickly ageing global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency, an incredibly exciting milestone for which we have been preparing for over a decade," said David Reese, MD, Executive VP and Chief Technology Officer at Amgen.
Som Chattopadhyay has been appointed national executive for India
Amgen India will initially build and accelerate new technology solutions and digital capabilities at scale that will enhance efficiencies across the enterprise.
The site will offer roles that strengthen key areas of Amgen's business, including AI, data science, life science and other additional global capabilities over time.
To lead Amgen's expanded presence in India, Som Chattopadhyay has been appointed national executive for India.
"Amgen's new site in Hyderabad underscores the city's position as a hub for innovation and technology," said Chief Minister Sri Anumula Revanth Reddy. "We are proud to welcome a global trailblazer of the biotechnology industry. Amgen's unwavering mission to serve patients will be incredibly inspiring for the world-class technology talent seeking to make a meaningful impact on people around the world."
Amgen has nearly 27,000 employees and has a presence in approximately 100 countries and regions worldwide, including India.
